NanoViricides CEO discusses NV-387's broad-spectrum antiviral potential

NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic NV-387. NV-387 was also shown to be effective against the orthopoxvirus family of viruses, which include Smallpox and Mpox, in both inhalation and skin abrasion modes of transmission. In a lethal animal model of lung infection by the Ectromelia virus, a model for Smallpox and Mpox infection in humans, NV-387 led to an increase in the mice's lifespan comparab ...